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We have previously shown that the glypican 3 (GPC3) gene was expressed in neuroblastoma (NB) and Wilms’ tumour (WT), two
embryonal tumours. GPC3 is an X-linked gene that has its peak expression during development and that is downregulated in all
investigated tissues after birth. GPC3 expression could be involved in the aetiology of embryonal tumours such as NB and WT.
Methylation is known to play a role in gene silencing, notably in chromosome X inactivation. Southern blot- and PCR-based
methylation assays were used to assess the methylation status of the GPC3 promoter on genomic DNA from both normal and
embryonal tumour cells. In normal cells, the promoter was not methylated in males and partially methylated in females. Our results
suggest that DNA methylation of the promoter region is not essential for the transcriptional repression of the GPC3 gene and that
the methylation observed in females is probably linked to the inactive X chromosome. In tumour samples, methylation abnormalities
have been found exclusively in female NB samples (loss of methylation) and mainly in male WT samples (gain of methylation).
Overall, methylation did not significantly correlate with the expression status of GPC3. Although promoter methylation is likely to
affect the expression status of the gene, our results suggest that the deregulation of GPC3 transcriptional expression seen in NB and
WT involves other regulatory levels.
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Glypican 3 (GPC3) gene has been shown to be expressed in
neuroblastoma (NB) and Wilms’ tumour (WT), two embryonal
tumours (Saikali and Sinnett, 2000; Toretsky et al, 2001). This gene
is expressed in a tissue-specific manner and has its peak
expression during development (Filmus et al, 1988; Hsu et al,
1997; Pellegrini et al, 1998). After birth, GPC3 is downregulated in
all investigated tissues (Filmus et al, 1988; Hsu et al, 1997;
Pellegrini et al, 1998). GPC3 is located at chromosome Xq26.1 and
spans more than 500kb (Pilia et al, 1996; Huber et al, 1997; Shen
et al, 1997). The gene product is a heparan sulphate proteoglycan
located on the cell surface and attached to the cellular membrane
by a glycosyl-phosphatidyl inositol anchor (Pilia et al, 1996). The
role of this protein is not yet exactly known. Many studies suggest
that GPC3 is a negative cellular growth regulator (Pilia et al, 1996;
Weksberg et al, 1996; Cano-Gauci et al, 1999; Lin et al, 1999;
Murthy et al, 2000; Xiang et al, 2001), one of the most compelling
evidence being that a germline mutation of the gene causes the
Simpson–Golabi–Behmel overgrowth syndrome (Pilia et al, 1996)
and that Gpc3 knockout mice partly recapitulate the syndrome
(Cano-Gauci et al, 1999). On the other hand, GPC3 has been shown
to be overexpressed in hepatocellular carcinomas (Hsu et al, 1997;
Toretsky et al, 2001; Zhu et al, 2001; Midorikawa et al, 2003) and to
be associated with advanced stages as well as with the invasive
potential of this cancer (Hsu et al, 1997). Moreover, colorectal
carcinoma-associated liver metastases express GPC3 significantly
more than primary tumours (Lage et al, 1998). These data suggest
that GPC3 is regulating different growth and survival factors in a
cell-dependent manner (Filmus, 2001).
The mechanisms regulating the transcription of GPC3 are of
particular interest to understand the altered expression of GPC3 in
cancer cells. GPC3 has been shown to be overexpressed
preferentially in female as compared to male hepatocellular
carcinomas (females, 95% and males, 67%) (Hsu et al, 1997). As
the gene is located on the X chromosome and DNA methylation is
implicated in chromosome X inactivation (Monk, 1986), this
observation raises the possibility that a loss of methylation could
be implicated in the overexpression of GPC3 in some cancer forms.
Hypermethylation of the GPC3 promoter associated with gene
silencing has been observed in certain adult cancers (Huber et al,
1999; Lin et al, 1999; Murthy et al, 2000; Xiang et al, 2001). Owing
to the potential involvement of GPC3 expression in the aetiology of
embryonal tumours, we tested the methylation status of the GPC3
promoter in DNA samples derived from both normal and
embryonal tumour cells.
MATERIALS AND METHODS
DNA samples
In this study, we used genomic DNA from the following sources: 14
peripheral blood samples (obtained from volunteer healthy donors
at the Sainte-Justine Hospital, Montreal, Canada); 11 placenta
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ssamples (DNA was obtained from C Deal); NB cell lines SK-N-AS,
SK-N-DZ, SK-N-FI, IMR-32, SK-N-SH (obtained from ATCC,
Manassas, VA, USA), NBL-S (obtained from GM Brodeur), SJNB-1,
SJNB-7, SJNB-10 (obtained from T Look); primary NB and WT
specimens (obtained from patients treated at Sainte-Justine
Hospital); and two peripheral blood samples from Turner
syndrome patients (DNA and karyotypes were obtained from C
Deal). This study was approved by our Institutional Review Board.
Methylation assays
Cytosine methylation assay The promoter region of GPC3
contains a CpG island (Figure 1A) (Huber et al, 1997). Several
attempts to apply bisulphite protocols (e.g. Cote et al, 1998) in
order to assess the methylation status of this promoter region were
unsuccessful (data not shown). This apparent resistance to
deamination is not unique to GPC3 (e.g. Bearzatto et al, 2000)
and could be explained by the high CG content (Harrison et al,
1998). We decided to use two alternative approaches (see below).
PCR-based methylation assay For the PCR-based method, 200ng
of genomic DNA and 200fg of a control plasmidic DNA construct
(pBlueScript vector with, as an insert, a 102bp HPRT gene
fragment containing three HpaII/MspI sites within position 1256–
1357, Accession number M26434) were digested with 100U of
HpaII or MspI (New England Biolabs, Beverly, MA, USA) for 16h
(see Benachenhou et al, 1998). The cleavage at the six HpaII/MspI
sites located within the 700bp upstream of the GPC3 transcription
initiation site was examined by the means of two PCR reactions
(one for the two distal sites and one for the four proximal sites;
Figure 1A). Polymerase chain reactions were performed in a total
volume of 20ml containing 1ml of the HpaII or MspI digestion
reactions (10ng of genomic DNA), 1  of ‘GC Genomic PCR
Reaction Buffer’ (Clontech, Palo Alto, CA, USA), 1.1mM
Mg(OAc)2, 200mM of each of the four dNTPs, 1 M ‘GC-Melt’
(Clontech, Palo Alto, CA, USA), 0.4mM of each primer (proximal
sites: B2 (ACGTGCTGCTACCCAGCCGCTGCA) and L2
(GGAACTTCTCCCAGAGCCAGTCAGAGCG); distal sites: E2
(CCGCTCATTGGCCTACAGCCTGGAGGGC) and J2 (TATT-
CAAAGGTGAGGCAGGCTGTGAAAAGC)) and 1  of ‘Advantage
GC Genomic Polymerase Mix’ (Clontech, Palo Alto, CA, USA).
Polymerase chain reactions for the proximal sites were performed
for one cycle of 951C for 1min, followed by 38 cycles of 951C for
45s, and 741C for 2min, followed by one cycle of 741C for 10min.
PCR reactions for the distal sites were performed for one cycle of
951C for 1min, followed by 28 cycles of 951C for 30s, and 681C for
Figure 1 Methylation analysis of the GPC3 promoter in nontumoural samples. (A) CpG dinucleotides positions in the GPC3 promoter region. The
methylation status of 11 of these CpG sites was determined either by the PCR-based methylation assay (#) or by the Southern blot-based methylation assay
(þ) using methyl-sensitive restriction endonucleases HpaII (H), SacII (S), EagI (E), and BssHII (B). HpaII contains one CpG site, whereas SacII, EagI and BssHII
contain two CpG sites each. The distal and proximal sites were amplified in distinct PCRs. (B and C) Representative results of the methylation analysis in
normal peripheral blood and placental DNA samples obtained by the PCR-based (B) and Southern blot-based (C) methylation assays. See Table 1 for
details concerning the samples. (D) PCR-based methylation assay performed on DNA samples from two individuals (AC-1 and DC) affected by the Turner
syndrome. Digestions: (B and D)H ,HpaII; M, MspI; U, undigested; (C)H ,HindIII; B, BssHII; S, SacII and E, EagI. GPC3þ, expression of GPC3; GPC3 ,n o
expression of GPC3.
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was verified by a PCR amplification of the control construct insert
with 1ml of the HpaII or MspI digestion reactions (10fg plasmid
DNA) under standard conditions.
Southern blot-based methylation assay Genomic DNA was
digested with HindIII, either alone or with methyl-sensitive
restriction endonucleases EagI, SacII or BssHII. The digestion
products were electrophoresed on agarose gels and transferred
onto Hybond Nþ nylon membranes (Amersham Pharmacia
Biotech, Baie d’Urfe ´, Canada). The membranes were hybridised
with a radiolabelled GPC3 promoter-specific PCR product (posi-
tions  969 to  346, Figure 1A). In this assay, a 6.1kb fragment is
expected when the investigated sites are fully methylated, whereas
a fragment of about 3kb should be obtained when the sites are not
methylated.
Statistical analysis
In order to evaluate whether methylation abnormalities was
significantly more frequent in female or male tumour samples,
the Fisher’s exact test was used. A methylation profile was
considered abnormal when it was different from the methylation
profile observed in apparently normal samples (peripheral blood
and placentas) of the same gender.
RESULTS
In all, 11 CpG sites located in the promoter of the GPC3 gene have
been tested for methylation using methyl-sensitive restriction
endonuclease assays (Figure 1A). Six of them were located within
HpaII sites and were tested by the PCR-based methylation assay
along with undigested and methyl-insensitive MspI-digested
samples as controls. The five others were located within EagI,
SacII and BssHII methyl-sensitive restriction sites and were
investigated with the Southern blot-based methylation assay.
These sites were first tested in DNA samples derived from
normal cells including 14 peripheral blood samples, known not to
express GPC3 (GPC3 ) (Hsu et al, 1997), and 11 placenta samples,
which strongly express GPC3 (GPC3þ) (Hsu et al, 1997). We
found that, independent of the expression status, methylation
correlated with the gender: females presented a partial methyla-
tion, whereas males had no methylation (Figure 1B and C). These
results suggest that methylation is not essential for the repression
of the GPC3 gene, since GPC3 nonexpressing male samples are not
methylated at the studied sites (Table 1). Southern blot methyla-
tion vs nonmethylation signal intensities presented a ratio of
approximately 1:1 in females, indicating the presence of methyla-
tion in about half of the DNA molecules (Figure 1C). This suggests
that the methylation detected in females could be linked to the
inactive X chromosome. Male sample #32 GPC3 promoter has been
shown to be partially methylated as opposed to other male samples
(Table 1). Sex determination assay and X chromosome micro-
satellite amplification (DXS102, DXS538 and DXS981) showed that
this sample has a Y chromosome and only one X chromosome
(data not shown). This suggests that the partial methylation seen in
sample #32 reflects cell heterogeneity for GPC3 promoter
methylation. PCR-based methylation assay on female sample #25
showed that at least one of the proximal sites was not methylated
(Table 1). However, the Southern blot-based assay methylation
profile of this sample was similar to that of the other female
samples, suggesting that the GPC3 promoter is methylated but not
at every site.
In order to test the hypothesis that GPC3 promoter methylation
in females is linked to the inactive X chromosome, the PCR-based
methylation assay was performed on peripheral blood DNA
samples from two Turner syndrome patients with karyotype (45,
Table 1 Summary of the GPC3 promoter methylation data of normal cells
Methylation status
PCR-based assay
a Southern blot-based assay
b
Sample Origin Gender
c Proximal sites Distal sites EagI SacII BssHII
GE Periph. blood F + + +/  +/  +/ 
CA Periph. blood F + + +/  +/  +/ 
UL Periph. blood F + + +/  +/  +/ 
CP41 Periph. blood F + + ND ND ND
CP42 Periph. blood F + + ND ND ND
CP43 Periph. blood F + + ND ND ND
GI Periph. blood M         
AL Periph. blood M         
HU Periph. blood M         
PED 93 Periph. blood M    ND ND ND
CP111 Periph. blood M    ND ND ND
CP112 Periph. blood M    ND ND ND
CP113 Periph. blood M    ND ND ND
CP114 Periph. blood M    ND ND ND
#11 Placenta F + + +/  +/  +/ 
#24 Placenta F + + +/  +/  +/ 
#25 Placenta F   ++ /   +/  +/ 
#26 Placenta F + + ND ND ND
#27 Placenta F + + ND ND ND
#28 Placenta F + + ND ND ND
#20 Placenta M    ND ND ND
#23 Placenta M    ND ND ND
#29 Placenta M         
#32 Placenta M + + ND +/  +/ 
#48 Placenta M         
GPC3¼glypican 3; PCR¼polymerase chain reaction.
a+¼methylated;  ¼not methylated.
b+¼methylation signal;  ¼nonmethylation signal; +/ ¼both methylation and
nonmethylation signals; ND¼not determined.
cF¼female; M¼male.
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detected (Figure 1D), supporting the hypothesis that the methyla-
tion signal detected at the GPC3 promoter is linked to the inactive
X chromosome.
PCR- and Southern blot-based methylation assays were
performed on the GPC3 promoter of NB cell lines, primary NBs
and primary WTs (Figure 2). Overall in NB samples, four females
out of six (67%) showed some loss of methylation, whereas every
males had normal methylation status (Figure 2, Table 2),
suggesting that methylation abnormalities are predominantly
found in females (Fisher’s test: P¼0.011). Methylation analysis
of the GPC3 promoter in WT samples also revealed abnormalities
when compared to the normal cells. One female out of four (WT51)
presented a loss of methylation and three males out of four (75%)
showed partial methylation (Figure 2, Table 2). Therefore, in
contrast to NB, in WT samples, methylation abnormalities seem to
Figure 2 Methylation analysis of the GPC3 promoter in tumour cell DNA samples. PCR- (A) and Southern blot- (B) based methylation assays were
performed on tumour cell DNA samples from NB cell lines (SK-N-AS, SK-N-SH), primary NBs (N4, N5) and primary WTs (WT51, WT116, WT158,
WT177). Only results for samples with abnormal DNA methylation patterns are shown. Digestions: (A)H :HpaII; M: MspI; U: undigested; (B)H :HindIII; B:
BssHII; S: SacII and E: EagI.
Table 2 Summary of the GPC3 promoter methylation data of tumour cells and their GPC3 mRNA expression status
Methylation status
PCR-based assay
a Southern blot-based assay
b
Sample Origin Gender
c Expression
d Proximal sites Distal sites EagI SacII BssHII
SK-N-AS NB cell line F +++   tr     
SK-N-SH NB cell line F ++   tr tr/  tr/  +/ 
SK-N-DZ NB cell line F   ++ + /   +/  +/ 
SJNB-1 NB cell line M ++         
SJNB-7 NB cell line M +++         
SJNB-10 NB cell line M +++    ND ND ND
NBL-S NB cell line M ++    ND ND ND
IMR-32 NB cell line M ++    ND ND ND
SK-N-FI NB cell line M          
NB4 Primary NB F + + + tr/  tr/  tr/ 
NB5 Primary NB F +   tr   tr/  tr/ 
NB8 Primary NB F ND + + ND ND ND
NB11 Primary NB M          
NB13 Primary NB M +         
NB193 Primary NB M ND    ND ND ND
WT130 Primary WT F ++ + + +/  +/  +/ 
WT42 Primary WT F + + + +/  +/  +/ 
WT51 Primary WT F ++   +     
WT106 Primary WT F + + ND ND ND ND
WT40 Primary WT M +++         
WT177 Primary WT M ++   tr +/  +/  +/ 
WT116 Primary WT M + tr   ND ND ND
WT158 Primary WT M ND tr + ND ND ND
GPC3¼glypican 3; PCR¼polymerase chain reaction; NB¼neuroblastoma; WT¼Wilms’ tumour.
a+¼methylated;  ¼not methylated.
b+¼methylation signal;
 ¼nonmethylation signal; tr¼traces; +/ ¼both methylation and nonmethylation signals; tr/ ¼both traces of methylation signal and nonmethylation signal; ND¼not
determined.
cF¼female; M¼male.
dTranscriptional expression:  ¼no expression; +¼weak expression; ++¼moderate expression; +++¼strong expression. The analysis of
the expression levels was reported in Saikali et al (2000) and was based on the visual inspection of all the Northern blots or semiquantitative RT–PCR assays.
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need to be investigated to confirm this trend (Fisher’s test:
P¼0.243).
In most cases, as in normal cells, the methylation pattern of the
GPC3 promoter at the investigated sites is not correlated with the
expression status (Table 2). However, in female NB samples, loss of
methylation correlates with the expression of GPC3 (Table 2),
raising the possibility that loss of methylation of the inactive X
chromosome could lead to the transcriptional activation of the
linked GPC3 allele. To test this hypothesis, the cell lines SK-N-DZ
(normal methylation pattern, GPC3 ; Table 2) and SK-N-SH (loss
of methylation, GPC3þ; Table 2) were treated with 0.5, 1 and 5mM
of demethylating agent 5-aza-deoxycytidine (5-aza-dC). Southern
blot-based methylation assay revealed that no demethylation was
achieved, and transcriptional expression was similar to the
nontreated controls as evaluated by Northern blot analysis (data
not shown), even in cells treated at highly toxic concentration of 5-
aza-dC (data not shown).
DISCUSSION
In this report, we showed in peripheral blood (GPC3 ) and
placental (GPC3þ) cells that the GPC3 promoter methylation
status at the investigated CpG sites was correlated with gender
rather than the expression status, male samples being unmethy-
lated and female samples being partially methylated. These
observations are consistent with those of another methylation
analysis of the GPC3 promoter performed on leucocyte DNA
samples (Huber et al, 1999).
These results indicate that methylation at these sites is not
essential for the repression of GPC3. However, we cannot exclude
the possibility that the CpG sites investigated are not critical for
the repression of the gene. The Southern blot-based methylation
assay that allows a quantitative analysis of methylation
taken together with the analysis of females with Turner syn-
drome support the hypothesis that the methylation observed in
females is associated with the inactive X chromosome. In this
regard, Huber et al (1999) have reported a complete methylation of
the GPC3 promoter in somatic hybrid hamster–human cells
containing only the human inactive X chromosome. These results
strongly suggest that the GPC3 allele located on the inactive X
chromosome is methylated, whereas the active X chromosome
allele is not. The methylation on the inactive X chromosome is
thought to be important for the maintenance of gene silencing
(Monk, 1986).
The methylation analysis in embryonal tumours revealed
methylation abnormalities particularly in female NB cells and in
male WTs. These observations might result from the fact that
cancer cells often present aberrant methylation, their genome
being generally hypomethylated and locally hypermethylated,
notably in CpG islands (Baylin et al, 1998; Momparler and
Bovenzi, 2000; Robertson and Jones, 2000). Our study suggests that
the main methylation abnormalities at the GPC3 promoter level
seems to be losses of methylation in NBs and the opposite in WTs.
Do methylation abnormalities have an influence on the expression
status of GPC3? In the embryonal tumour cells tested, as in normal
cells, we failed to observe any correlation between methylation and
expression of GPC3. However, it has been shown in vitro that the
GPC3 promoter does not activate the transcription of a reporter
gene when methylated (Huber et al, 1999). In light of these results,
it seems likely that the transcriptional activation of the GPC3 gene
requires an absence of methylation of the gene promoter, but that
the absence of methylation alone does not necessarily lead to
transcriptional activity. It is thus possible that the loss of
methylation we observed in female NBs allows the inactive X
chromosome GPC3 allele to become transcriptionally active,
eventually leading to a dosage effect in the corresponding cells.
The same mechanism could also explain the preferential over-
expression of GPC3 in women affected with hepatocellular
carcinomas (Hsu et al, 1997).
In summary, in vivo DNA methylation of the promoter regions
does not seem to be the predominant regulatory mechanism for
the GPC3 gene. Thus the apparent deregulation of the GPC3 mRNA
expression reported in embryonal tumours (Saikali and Sinnett,
2000) is likely to involve other regulatory signals.
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